Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.39 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307180 | 0.75 | HSP90AA1 (0.57) | HSP90AB1HSP90AA1 | |
| SCHEMBL6309367 | 0.68 | HSP90AB1 (0.39) | HSP90AB1HSP90AA1 | |
| SCHEMBL3631158 | 0.67 | HSP90AB1 (0.71) | HSP90AB1HSP90AA1 | |
| SCHEMBL8071682 | 0.67 | HSP90AB1 (0.71) | HSP90AB1HSP90AA1 | |
| SCHEMBL5075028 | 0.67 | MAPT (0.49) | HSP90AB1HSP90AA1HTT | |
| SCHEMBL6308343 | 0.67 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1 | |
| SCHEMBL24831529 | 0.66 | MEN1 (0.36) | HTT | |
| SCHEMBL6315112 | 0.65 | HSP90AA1 (0.52) | HSP90AB1HSP90AA1 | |
| SCHEMBL6315157 | 0.65 | HSP90AA1 (0.60) | HSP90AB1HSP90AA1 | |
| SCHEMBL7054559 | 0.65 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919339-B2 | ABCA-1 elevating compounds | CV THEAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | HSP90AB1 1191/4885HSP90AA1 1676/4885PTPRF 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.